Home › Compare › OISXF vs ABBV
OISXF yields 1.25% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, OISXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OISXF + ABBV for your $10,000?
Oisix ra daichi Inc. engages in the online and catalogue sale of organic vegetables, agricultural products, additive free processed foods, and other food products and ingredients to general consumers in Japan. The company offers food products through Oisix stores; Oisix order services that enables consumers to order hard to find seasonal products; Oitoku, a regular delivery services that provides customers with pre-registered products at discounted prices; Daichi wo mamorukai, a household delivery services for organic agricultural products; and Tavelty for seasonal vegetable novelty packs. In addition, it offers advertising services; solutions support to companies for repeat sales; website user interface/user experience enhancement; temperature-controlled food distribution; new online customer acquisitions; and know-how on omni-channel retailing. The company was formerly known as Oisix.daichi Inc., and changed its name to Oisix ra daichi Inc. in July 2018. Oisix ra daichi Inc. was incorporated in 1997 and is headquartered in Tokyo, Japan.
Full OISXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.